GlassScriptPhysician profile
Charles W Taylor
NPI 1003859679
$1,333.82
in general payments reported to CMS, 2019-2025
24 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $107 · 2021: $157 · 2022: $150 · 2023: $130 · 2024: $195 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675 · Education: $93.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $675.46 |
| Education | $93.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $373.22 | 2019-2025 | Calquence, Imfinzi |
| Pfizer INC. | $190.02 | 2019-2024 | |
| Caris Mpi, INC. | $136.60 | 2025 | Mi Cancer Seek |
| Glaxosmithkline, LLC. | $68.41 | 2020-2025 | Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $67.76 | 2021-2024 | Opdivo |
| Novartis Pharmaceuticals Corporation | $64.25 | 2022-2023 | |
| Genzyme Corporation | $51.75 | 2022-2024 | |
| Astellas Pharma US INC | $51.44 | 2020-2025 | Vyloy |
| Ipsen Biopharmaceuticals, INC | $48.69 | 2024 | Tazverik, Onivyde |
| Celgene Corporation | $41.52 | 2021 | |
| Gilead Sciences, INC. | $35.82 | 2021 | |
| Genmab U.S., INC. | $33.16 | 2024 | Epkinly |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Seagen INC. | $23.08 | 2020 | |
| Taiho Oncology, INC. | $22.72 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.00 | 2023 | Venclexta |
| Boston Scientific Corporation | $21.57 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Daiichi Sankyo INC. | $21.43 | 2020 | |
| Agios Pharmaceuticals, INC. | $19.38 | 2024 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $17.07 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.